Kristen Williams insider trades: Pacira BioSciences (PCRX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Kristen reports to the SEC
Open-market buys and sales
26 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | PCRX | ↓ Sell10b5-1 | 13,137 | $20.53 | $270K | Direct | Feb 3, 2026 (1d) |
| Jun 4, 2025 | PCRX | ↓ Sell | 14,376 | $26.24 | $377K | Direct | Jun 5, 2025 (1d) |
| Jun 13, 2024 | PCRX | ↓ Sell | 7,452 | $28.38 | $211K | Direct | Jun 13, 2024 (0d) |
| Jun 14, 2023 | PCRX | ↓ Sell | 6,467 | $37.03 | $239K | Direct | Jun 16, 2023 (2d) |
| Jun 7, 2023 | PCRX | ↓ Sell | 2,658 | $38.42 | $102K | Direct | Jun 7, 2023 (0d) |
| Jun 7, 2022 | PCRX | ↓ Sell | 8,618 | $60.37 | $520K | Direct | Jun 8, 2022 (1d) |
| Mar 21, 2022 | PCRX | ↓ Sell | 7,253 | $72.67 | $527K | Direct | Mar 23, 2022 (2d) |
| Feb 25, 2022 | PCRX | ↓ Sell | 2,060 | $67.01 | $138K | Direct | Mar 1, 2022 (4d) |
| Feb 10, 2022 | PCRX | ↓ Sell | 800 | $65.18 | $52K | Direct | Feb 14, 2022 (4d) |
| Feb 4, 2022 | PCRX | ↓ Sell | 1,000 | $65.18 | $65K | Direct | Feb 8, 2022 (4d) |
| Jan 21, 2022 | PCRX | ↓ Sell | 200 | $65.41 | $13K | Direct | Jan 25, 2022 (4d) |
| Jan 19, 2022 | PCRX | ↓ Sell | 25,639 | $65.28 | $1.7M | Direct | Jan 20, 2022 (1d) |
| Jun 10, 2021 | PCRX | ↓ Sell | 5,689 | $59.60 | $339K | Direct | Jun 11, 2021 (1d) |
| Jun 4, 2021 | PCRX | ↓ Sell | 3,930 | $61.04 | $240K | Direct | Jun 8, 2021 (4d) |
| Apr 13, 2021 | PCRX | ↓ Sell | 21,823 | $66.95 | $1.5M | Direct | Apr 15, 2021 (2d) |
| Sep 17, 2020 | PCRX | ↓ Sell | 83,577 | $59.78 | $5.0M | Direct | Sep 17, 2020 (0d) |
| Jun 5, 2020 | PCRX | ↓ Sell | 8,306 | $47.95 | $398K | Direct | Jun 8, 2020 (3d) |
| Aug 14, 2019 | PCRX | ↓ Sell | 6,252 | $39.49 | $247K | Direct | Aug 16, 2019 (2d) |
| Jun 4, 2019 | PCRX | ↓ Sell | 2,529 | $42.91 | $109K | Direct | Jun 6, 2019 (2d) |
| Aug 14, 2018 | PCRX | ↓ Sell | 4,773 | $47.04 | $225K | Direct | Aug 16, 2018 (2d) |
| Jun 4, 2018 | PCRX | ↓ Sell | 2,040 | $33.02 | $67K | Direct | Jun 6, 2018 (2d) |
| Nov 17, 2017 | PCRX | ↓ Sell | 10,000 | $40.00 | $400K | Direct | Nov 20, 2017 (3d) |
| Aug 15, 2017 | PCRX | ↓ Sell | 3,461 | $36.75 | $127K | Direct | Aug 17, 2017 (2d) |
| Jun 5, 2017 | PCRX | ↓ Sell | 1,877 | $43.32 | $81K | Direct | Jun 7, 2017 (2d) |
| May 15, 2017 | PCRX | ↓ Sell | 21,041 | $50.86 | $1.1M | Direct | May 17, 2017 (2d) |
| Jun 6, 2016 | PCRX | ↓ Sell | 600 | $47.20 | $28K | Direct | Jun 8, 2016 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other PCRX insiders
Open-market trades in the last 12 months
About Kristen Williams's insider trades
Kristen Williams is Chief Administrative Officer at Pacira BioSciences (PCRX). Since Jun 6, 2016, Kristen has reported no open-market purchases and 26 sales worth $14.0M on SEC Form 4. In the last 12 months: 1 sale ($270K).
1 sale (2% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include grants and awards (14 filings), option exercises (10 filings), shares withheld for taxes (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PCRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.